The federal government is about to flip the switch on a massive financial engine for healthcare technology, but most of Silicon Valley hasn’t even noticed the countdown. As the United States grapples with a tightening national budget and the economic ripple effects of the ongoing conflict in Iran, the Centers for Medicare & Medicaid Services (CMS) is turning to automation to slash costs. Starting July 1, 2026, a new 10-year program called the ACCESS model will begin fundamentally changing how the government pays for chronic care. It is a bold move that moves away from paying for “visits” and starts paying for “results” generated by artificial intelligence.
This initiative, formally known as Advancing Chronic Care with Effective Scalable Solutions, is a complete departure from the old-school fee-for-service system. Under the new rules, healthcare providers will use AI agents, ambient scribes, and remote monitoring tools to manage patients with chronic conditions between their actual doctor appointments. The goal is to keep people out of the hospital by using constant digital oversight. But there is a catch that has many traditional tech firms hesitating. Medicare is putting half of the money in escrow, essentially telling companies that their tech has to actually work if they want to get paid in full.
The 50 Percent Gamble: Proving AI Results in Real Time
The core of this technology shift is a mechanism called Outcome-Aligned Payments (OAP). It works like a high-stakes performance contract. CMS will send out 50% of the payment on a recurring monthly basis to cover the costs of the AI and monitoring software. However, the other 50% is withheld. This money is only released after 12 months if the provider can prove the patient’s health actually improved. The detailed report by Medical Office Force confirms this structure is designed to transfer the financial risk of patient health directly onto the software developers and clinical practices.
For a tech company, this means “software as a service” is becoming “software as a result.” If the AI fails to engage a patient or misses a critical data point that leads to a hospital stay, the company loses its profit margin. This 10-year commitment is a massive windfall for those who can execute, yet the complexity of the regulatory language has kept it under the radar for many mainstream venture capital firms. They are used to predictable subscription fees, not the messy world of clinical outcomes.
Clinical Targets That Trigger the Windfall
The rewards aren’t just handed out for “using AI”—they are tied to very specific biological benchmarks. To unlock the withheld funds, at least half of a practice’s patients must hit strict numbers. This includes a 15 mmHg reduction in systolic blood pressure or a 1% drop in HbA1c levels for diabetics. According to research by ATI Advisory, the ACCESS model specifically targets cardio-kidney-metabolic tracks, chronic pain, and depression. These are the most expensive conditions for the government to manage, and they believe AI-driven call handling and automated data tracking are the only ways to handle the sheer volume of patients.
Providers are already scrambling to find partners that can handle “care leakage.” This happens when a patient goes to an emergency room instead of using the digital tools provided to them. Under the ACCESS model, every “leaked” patient is a hit to the provider’s bottom line. The tech has to be more than just a fancy dashboard. It has to be an active participant in the patient’s life, nudging them to take medication and alerting doctors before a crisis happens. It is a high-pressure environment where code meets biology.
How the ACCESS Model Shift Favors Health-Tech Giants Over Startups
The move to outcome-based payments creates a massive barrier to entry for smaller AI startups. While the potential for 10 years of guaranteed Medicare revenue is a dream for any CFO, the 50% withhold rule requires significant cash reserves. Established entities like Omada Health or Hinge Health already have the infrastructure to absorb a year of delayed payments while they wait for their clinical data to be verified. A smaller startup, however, might run out of runway before Medicare releases the escrowed funds. This paradigm shift effectively forces a consolidation in the market, where only the most financially stable and clinically proven AI platforms will survive the 2026 rollout.
Historically, this is the first time the federal government has explicitly built a multi-year reimbursement pipeline around the assumption that AI can replace manual human outreach. It signals a move toward a “virtual first” healthcare system. For the tech world, the takeaway is clear: the era of selling “cool features” to doctors is over. In the ACCESS era, if your algorithm doesn’t lower blood pressure, it doesn’t get paid. This is the ultimate stress test for medical AI, and the July 1 launch will determine which companies become the next healthcare titans and which ones were just hype.